IMPERIAL trial shows Eluvia outperforms Zilver PTX at one year

Andrew Holden (Auckland, News Zealand) interviews Stefan Mueller-Huelsbeck (Flensburg, Germany) to distil the key findings of the IMPERIAL trial one-year data that were presented for the very first time at CIRSE 2018 in Lisbon.

In the randomised controlled trial, Eluvia, which utilises a drug-polymer combination to offer sustained release of the drug paclitaxel, showed higher rates of primary patency at 12 months. Patients in the Eluvia arm of the study also experienced higher rates of freedom from target lesion revascularisation when compared to those treated with Zilver PTX.

Holden, Andrew

Andrew Holden is the director of interventional radiology at Auckland Regional Public Health Service and associate professor of Radiology at Auckland University School of Medicine in Auckland, New Zealand. He has been involved in the investigation of several endovascular devices for the treatment of abdominal aortic aneurysms and peripheral arterial disease

Add comment

    Subscribe to receive the very best in medical videos

    /* ]]> */